### NOTIFICATION TO RESE

Public reporting burden for this collection of information is estin time to review instructions, search existing data sources, gathe information. An agency may not conduct or sponsor, and a pers displays a current, valid OMB control number.

Send comments regarding this burden estimate or any other as the burden to

NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 79 Do not return the completed form to this address. OMB#: 0925-0600 EXP. DATE: 3/31/13

### 20NDENT OF ESTIMATED BURDEN

nated to average sixty (60) minutes for this questionnaire, including the r and maintain the data needed, and complete and review the collection of on is not required to respond to, a collection of information unless it

spect of this collection of information, including suggestions for reducing

74, Bethesda, MD 20892-7974, ATTN: PRA (0925-0600).

### CTRP Trial Registration Batch Upload Specification for Abl

#### **About this Document**

This document provides you with everything you need to upload clinical trial data to the CT

#### **Template Instructions**

The Template Instructions worksheet provides detailed instructions for preparin

### **Sample Trial Data**

The Sample Trial Data worksheet provides an example of what a typical batch u Note: A batch upload file must contain only one (1) worksheet (tab)

### **Batch Upload Data Element Specifications**


The specifications worksheet includes the following information:

- 1 Data elements
- 2 Order in which the data elements *must be* presented
- 3 Data element requirements. Requirements differ for original updated
- 4 Valid values. The system accepts only those values listed in this doc
- 5 Comments. Additional information that helps you to ensure success

#### **State and Provence Codes**

The State and Province Codes worksheet lists the 2- or 3-letter state/province/to

# previated Trials



# **How to Subr**

### **Before You Be**

Contact the CTRO

Note: Once you ha

## Main Steps fo

- 1 Prepare t
- 2 Email you

Note: CTRO staff v
To transfer trial ow

## **Preparing Tri**

- 1 Ensure th
  - \* Interv
  - \* Abbr
  - \* Upda
  - \* 100 t
- 2 Prepare a

#### You mus

- \* List trial
- \* Do not (
- \* Conforn
- \* Identify
- \* If you pi
- \* If a trial
- \* If more
- \* List per

# **Emailing You**:

Email your file as  $\boldsymbol{\epsilon}$ 

For detailed instructure https://wiki.

## nit Abbreviated Trial Data to the CTRP Trial Registration System

### egin

at ncictro@mail.nih.gov to request approval for sending batch files to CTRP. Include your login name, first received approval, you do not have to request approval for subsequent batches.

### r Uploading Your Data

he trial data file ur files to the CTRO at ncictro@mail.nih.gov

will register your trials using your batch file data. As the trial submitter, the CTRO maintains trial ownership mership email the CTRO with the first name, last name and email address of the person who will manage y

### ial Data Files

nat your trial conforms to the supported criteria. This template supports the following:

rentional trials eviated trials (Summary 4 Funding Sponsor Category is Industrial) ates to abbreviated CTRP trials with the processing status "Accepted" and beyond rials per data file

an Excel spreadsheet (.xls) containing the mandatory and optional data for the trial(s) as specified in this d

#### it adhere to the following requirements:


elements required for registration in the order specified in the Abbreviated Trial Data Spec tab in this sprechange the spelling of data elements or valid values. Changes to spelling or to the order of the trial element not the valid values guidelines when entering trial data. Valid values for each of the trial elements, where a each trial uniquely. For example, append your cancer center unique trial identifier to the file name. rovide an NCT number the primary purpose, phase, disease and intervention data are not required. is identified as a duplicate to an existing trial, you can request to add your organization information to the than one disease or intervention is included, list them on additional lines, one per line when adding local sons and organizations with PO-IDs.

Note: You can request a list of CTRP persons and organizations along with PO-IDs from the CTRO at ncictro@mail.nih.gov. IDs.

## r Files

an attachment to the CTRO at ncictro@mail.nih.gov.

ctions for registering trials, refer to the NCI CTRP Reporting Program Registration Site User's Guide at: <a href="https://nci.nih.gov/x/7qViAw">nci.nih.gov/x/7qViAw</a>





						_
Local	Submissi	NCI Trial	[Submitting	[Submitting	[Submitting	[Submitting
Trial	on Type	Identifier	[Submitting Organization] Organization PO-ID	[Submitting Organization]	[Submitting Organization] Street Address	[Submitting Organization] City
Identifier			Organization	Name	Street Address	City
			PO-ID			
1	0			Mayo Clinic	5777 East	Phoeniz
				Hospital	Mayo	
					Boulevard	
1						
	1					
	<u> </u>					
	-					
	ļ					
	<u> </u>					

[Submitting Organization] State/Province	[Submitting Organization] Zip/Postal code	[Submitting Organization] Country	Address	[Submitting Organization ] Phone	[Submitting Organizatio n] TTY	[Submitting Organization] FAX
AZ	85054	United States	ncictepcoppa services@mai l.nih.gov			


[Submitting Organization ] URL	[Submitting Organization] Organization Type	Is Submitting Organization a NCI Designated	[Lead Organization] CTEP Organization	[Lead Organization] Name	[Lead Organization] Street Address	[Lead Organization] City
		Cancer Center?	PO-ID			
	Research Based	Yes	12345			

•			

[Lead Organization] State/Province	[Lead Organization] Zip/Postal code	[Lead Organization] Country	[Lead Organization] Email Address	[Lead Organization] Phone	[Lead Organization] TTY	[Lead Organization] FAX


rı ı	r		NOT T : :		<b>-</b> · · -	n :	I.C.D.:
[Lead Organization] URL	[Lead Organization] Organization Type	Lead Organization Trial Identifier	NCT Trial Identifier	Title	Trial Type	Primary Purpose	If Primary Purpose is 'Other', describe
	cancer center			Phase III study of priming with granulocy te- macropha ge colony stimulatin	Interventi onal	Other	Laborator y

Phase	Pilot Trial?	[Site Principal Investigator] Person PO-ID	[Site Principal Investigator] First Name	[Site Principal Investigator] Middle Name	[Site Principal Investigator] Last Name
III			Harry		Long

[Site Principal Investigator] Street Address	[Site Principal Investigator] City	[Site Principal Investigator] State/Province	[Site Principal Investigator] Zip/Postal code	[Site Principal Investigator] Country
5777 East Mayo Boulevard	Phoeniz	AZ	85054	United States

[Site Principal Investigator] Email Address	[Site Principal Investigator] Phone	[Site Principal Investigator] TTY	Site [Principal Investigator] FAX	[Site Principal Investigator] URL
Harry.Long@mayo	123-345-7654			

Summary 4 Funding Sponsor/Sourc e Category	[Summary 4 Funding Sponsor/Sourc e] Organization PO-ID	[Summary 4 Funding Sponsor/Sourc e] Organization Name	[Summary 4 Funding Sponsor/Sourc e] Street Address	[Summary 4 Funding Sponsor/Sourc e] City	[Summary 4 Funding Sponsor/Sourc e] State/Province
Industrial		Novartis Pharmaceutical s Corporation	One Health Plaza	East Hanover	NJ

	!		

[Summary 4 Funding Sponsor/Sourc e] Zip/Postal code	[Summary 4 Funding Sponsor/Sourc e] Country	[Summary 4 Funding Sponsor/Sourc e] Email Address	[Summary 4 Funding Sponsor/Sourc e] Phone	[Summary 4 Funding Sponsor/Sourc e] TTY	[Summary 4 Funding Sponsor/Sourc e] FAX
07936-1080	United States	ncictepcoppas ervices@mail.n ih.gov			

	!		

[Summary 4 Funding Sponsor/Sourc e] URL	[Submitting Site specific] Program Code	Site Recruitm ent Status	Site Recruitm ent Status Date	Date Opened for Accrual	Date Closed for Accrual	Disease Name
		Active	03/01/200 9	03/01/2009		acute non- lymphocy tic leukemia
						stage III non- lymphocy tic leukemia


Interventi		Trial	Trial	Trial	
on Type	on Name	Owner	Owner	Owner	
		First	Last	Email	
		Name	Name	Address	
Biological	granulocy	Mary	Smith	m.smith@i	
\/accine	granulocy te-	111.61.7		inionital (e)	
/ Vaccinc	macropha				
	de colony				
	ge colony stimulatin				
	g factor				
	y iacioi				
	L	<u> </u>	L	<u> </u>	


Trial elements Order	Trial data element	Required?
1	Local Trial Identifier	Yes
2	Submission Type	Yes
3	NCI Trial Identifier	Yes for submitting update only
4	[Submitting Organization] Organization PO-ID	
5	[Submitting Organization] Name	Yes if PO-ID is not provided
6	[Submitting Organization] Street Address	Yes if PO-ID is not provided
7	[Submitting Organization] City	Yes if PO-ID is not provided
8	[Submitting Organization] State/Province	Yes for US/Canada/Australia and if PO-ID is not provided
9	[Submitting Organization] Zip/Postal code	Yes if PO-ID is not provided
10	[Submitting Organization] Country	Yes if PO-ID is not provided
11	[Submitting Organization] Email Address	Yes if PO-ID is not provided
12	[Submitting Organization] Phone	
13	[Submitting Organization] TTY	
14	[Submitting Organization] FAX	
15	[Submitting Organization] URL	
16	[Submitting Organization] Organization Type	
17	Is Submitting Organization a NCI Designated Cancer Center?	Yes
18	[Lead Organization] CTEP Organization PO-ID	
19	[Lead Organization] Name	Yes if PO-ID is not provided

20	[Lead Organization] Street Address	Yes if PO-ID is not provided
21	[Lead Organization] City	Yes if PO-ID is not provided
22	[Lead Organization] State/Province	Yes for US/Canada/Australia and if PO-ID is not provided
23	[Lead Organization] Zip/Postal code	Yes if PO-ID is not provided
24	[Lead Organization] Country	Yes if PO-ID is not provided
25	[Lead Organization] Email Address	Yes if PO-ID is not provided
26	[Lead Organization] Phone	Yes if PO-ID is not provided
27	[Lead Organization] TTY	
28	[Lead Organization] FAX	
29	[Lead Organization] URL	
30	[Lead Organization] Organization Type	
31	Lead Organization Trial Identifier	Yes
32	NCT Trial Identifier	
33	Title	Yes
34	Trial Type	Yes
35	Primary Purpose	Yes, if NCT number is not provided
36	If Primary Purpose is 'Other', describe	Yes, if Primary Purpose value is 'Other'

37	Phase	Yes, if NCT number is not provided
38	Pilot Trial?	
39	[Site Principal Investigator] Person PO-ID	
40	[Site Principal Investigator] First Name	Yes if PO-ID is not provided
41	[Site Principal Investigator] Middle Name	
42	[Site Principal Investigator] Last Name	Yes if PO-ID is not provided
43	[Site Principal Investigator] Street Address	Yes if PO-ID is not provided
44	[Site Principal Investigator] City	Yes if PO-ID is not provided
45	[Site Principal Investigator] State/Province	Yes for US/Canada/Australia and if PO-ID is not provided
46	[Site Principal Investigator] Zip/Postal code	Yes if PO-ID is not provided
47	[Site Principal Investigator] Country	Yes if PO-ID is not provided
48	[Site Principal Investigator] Email Address	Yes if PO-ID is not provided
49	[Site Principal Investigator] Phone	Yes if PO-ID is not provided
50	[Site Principal Investigator] TTY	
51	Site [Principal Investigator] FAX	
52	[Site Principal Investigator] URL	
53	Summary 4 Funding Sponsor/Source Category	Yes
54	[Summary 4 Funding Sponsor/Source] Organization PO-ID	PO-ID or the rest of mandatory attribute for the organization is mandatory
55	[Summary 4 Funding Sponsor/Source] Organization Name	Yes if PO-ID is not provided
56	[Summary 4 Funding Sponsor/Source] Street Address	Yes if PO-ID is not provided

57	[Summary 4 Funding Sponsor/Source] City	Yes if PO-ID is not provided
58	[Summary 4 Funding Sponsor/Source] State/Province	Yes if PO-ID is not provided and for the following courtiers: USA, Canada and Australia
59	[Summary 4 Funding Sponsor/Source] Zip/Postal code	Yes if PO-ID is not provided
60	[Summary 4 Funding Sponsor/Source ] Country	Yes if PO-ID is not provided
61	[Summary 4 Funding Sponsor/Source ] Email Address	Yes if PO-ID is not provided
62	[Summary 4 Funding Sponsor/Source ] Phone	
63	[Summary 4 Funding Sponsor/Source ] TTY	
64	[Summary 4 Funding Sponsor/Source ] FAX	
65	[Summary 4 Funding Sponsor/Source ] URL	
66	[Submitting Site specific] Program Code	Yes for NCI designated cancer center
67	Site Recruitment Status	Yes
68	Site Recruitment Status Date	Yes
69	Date Opened for Accrual	Yes if study is or was opened for accrual
70	Date Closed for Accrual	Yes if study is or was closed for accrual
71	Site Target Accrual	Yes for NCI designated Cancer Center
72	Disease Name	Yes if NCT number is not provided
73	Intervention Type	Yes if NCT number is not provided

74	Intervention Name	Yes if NCT number is not provided
75	Trial Owner First Name	Yes
76	Trial Owner Last Name	Yes
77	Trial Owner Email Address	Yes

Valid Values	Comments	Definition
Talla Valaoo		
	Trial identifier as assigned	
	by the submitting organization	
O, U	O- Original is default. U- update	Original submission is the first time submission of a trial to CTRP. Update means submitting an update to the already registered trial in CTRP.
	Ignored in case of original submission	
	PO-ID or all organization mandatory attributes are required	
2-letter state/province code required for US/Canada, 2-3 letter code required for Australia		
	Landa de Bhana E tanaina is	
	Include Phone Extension if any in the same field	
Institution, ordering group, repository, research based, cooperative group, cancer center, consortium, drug company, network		
yes, no	no is default	
	PO-ID or all organization mandatory attributes is required	

	1	
2-letter state/province code required for US/Canada, 2-3 letter code required for Australia		
	Include Phone Extension if any in the same field	
Institution, ordering group, repository, research based, cooperative group, cancer center, consortium, drug company, network		
	AS IS in the protocol document & assigned by the lead organization	
	This value or at least one disease and one intervention record are required in attached proprietary trial template	
Max 4000 characters	Title from the protocol document	
Interventional, Observational	Currently only Interventional trials are accepted	
Treatment, Prevention, Supportive Care, Screening, Diagnostic, Health Service Research, Basic Science, Other	Mandatory if value in row 32 is NULL (if NCT number is NULL)	
	Provide free text value if Primary Purpose value is 'Other'. Not aplicable if Primary Purpose is not 'Other'	

[	1	
0, I, I/II, II, II/III, III, IV, N/A	Mandatory if value in row 32 is NULL (if NCT number is NULL)	
Yes, No	Only applicable if Phase is 'N/A; Default is No	
	PO-ID or all mandatory person attributes are required	
2-letter state/province code required for US/Canada, 2-3 letter code required for Australia		
	Include Phone Extension if any in the same field	
Industrial		
Industrial		
[	1	

2-letter state/province code required for US/Canada, 2-3 letter code required for Australia		
Submitting Site specific	Submitting Site specific, 'Not specified' is default. Mandatory if value in row 17 is 'yes'.	
Not yet recruiting; Recruiting; Enrolling by invitation; Active, not recruiting; Completed; Suspended; Terminated; Withdrawn		
	Date when the recruitment status has come in effect	
	Mandatory if value in row 17 is 'yes'. '0' can be used if value is unknown	
	If more that one disease is provided, use the additional line for a new disease (see Trial Data Sample)	
Drug, Device, Biological/Vaccine, Procedure/Surgery, Radiation, Behavioral, Genetic, Dietary Supplement, Other	If more that one intervention is provided, use the additional line for an additional intervention (see Trial Data Sample)	

If more that one intervention is provided, use the additional line for an additional intervention (see Trial Data Sample)	
This information is required for trial ownership transfer. Note: user must be registered in CTRP	
This information is required for trial ownership transfer. Note: user must be registered in CTRP	
This information is required for trial ownership transfer. Note: user must be registered in CTRP	

## Country 3-letter code State/Province

**UNITED STATES** 

USA

Alabama

Alaska

Arizona

Arkansas

California

Colorado

Connecticut

Delaware

Florida

Georgia

Hawaii

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

N 4 - ... .l - ... .

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

**New Hampshire** 

**New Jersey** 

**New Mexico** 

New York

North Carolina

North Dakota

Ohio

Oklahoma

Oregon

Pennsylvania

Rhode Island

South Carolina

South Dakota

Tennessee

Texas

Utah

Vermont

Virginia

Washington

West Virginia

		Wisconsin Wyoming
CANADA	CAN	,
		Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon
AUSTRIA	AUT	
ACCITION	AUT	Australian Capital Territory New South Wales Northern Territory Queensland South Australia Tasmania Victoria

Western Australia

## 2-3 letter state/province code Old values

AL AK

\ \ \ \

ΑZ

AR CA

СО

СТ

DE

FL

GΑ

ΗΙ

ID

IL

IN

IA KS

KY

LA

ME MD

MA

MΙ

MN

MS

МО

MT NE

NV

NH

NJ

NM

NY

NC

ND

ОН

OK

OR PA

RI

SC

SD

TN

TX

UT VT

VA

WA

WV

WI WY

AΒ

ВС

MB NB

NL

NT

NS

NU ON

PE

QC

SK YT

ACT

NSW

NT

QLD

SA TAS

VIC

WA